Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

safenolaTiCancerDrug

Financiado

Cerrado

Highly and Widely Effective Water Stable and Non Toxic Titanium Phenolato base...

Highly and Widely Effective Water Stable and Non Toxic Titanium Phenolato based Anticancer Chemotherapy Chemotherapy is the most common line of treatment for various cancer types, but it generally suffers from severe side effects. Cisplatin is a highly effective metallodrug employed in the clinic, limited by severe and irreversible... ver más

30/04/2019

THE HEBREW UNIVERS...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-04-30

ERC-2017-PoC: ERC-Proof of Concept

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

THE HEBREW UNIVERSITY OF JER...

150.00K€ | Lider

SOCIEDAD COOPERATIVA GANADER...

637.71K€ | Participante

Proyectos interesantes

CYTOTOXICTISALANS

Medical Technol...

Materials Scien...

168K€ Cerrado

PID2021-125746OA-I00

Medical Technol...

Chemical Engine...

157K€ Cerrado

CTQ2015-68779-R

Medical Technol...

Chemical Engine...

113K€ Cerrado

SAF2009-09431

Medical Technol...

Chemical Engine...

266K€ Cerrado

CTQ2014-52949-P

Medical Technol...

Chemical Engine...

105K€ Cerrado

CTQ2008-04873

Medical Technol...

Chemical Engine...

121K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2017-10-18
Fecha Fin: 2019-04-30

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chemotherapy is the most common line of treatment for various cancer types, but it generally suffers from severe side effects. Cisplatin is a highly effective metallodrug employed in the clinic, limited by severe and irreversible nephro- and neurotoxicities and resistance development. Therefore, developing highly and widely effective chemotherapy that is non- or substantially less- toxic should impact immediately and significantly the welfare of society. The titanium metal is an attractive Pt alternative, as it is bio-friendly and non-toxic. Titanium dioxide, the final decomposition product of Ti complexes in water, is a safe material often found in food and cosmetics. Nevertheless, the rapid dissociation of past Ti complexes in water has hampered their development into drugs. Under an ERC-StG grant followed by an ERC-CoG grant, the PI has developed Ti(IV) complexes that are stable for weeks in water, with high in vitro activity toward numerous cells (also established on the NCI-60 panel of the NIH) and in vivo toward murine and human models with no clinical sights of toxicity in treated mice at effective doses, where mortality occurred in control animals treated with cisplatin at similar doses. Pharmaceutical entities have shown specific interest in taking the proposed compound 1 into clinical trials phase I. Some experiments are still required before an agreement can be made, as proposed herein. Through the parent ERC-CoG, mechanistic analyses are ongoing, but no animal studies are permitted. Thus, through the proposed study: (a) pharmacokinetic studies on compound 1 by ICP-MS will determine absorption, bio-distribution, and excretion; (b) In vivo studies of different models and with varying concentrations and formulation types will determine the therapeutic potential; (c) iv vivo combination studies will identify possible lines of treatments. These studies should promote the interaction with pharmaceutical companies to enable compound 1 to enter clinical trials.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores